Join us for our webcast, 2025 Tax Strategies for Health Care Leaders, designed to help you prepare for 2025 tax strategies under the new administration. You’ll learn insights to reduce your tax burden in 2025 and more. 

We’ll address:

• Insights on how tax consequences are critical to ongoing operations as well as the M&A markets
• Tax reform proposals promoted by President Trump
• Tax credits and incentives available for health care and health tech organizations
• Proposed changes to the interest deduction limitation rules from the Tax Cuts and Jobs Act (TCJA) which currently costs many health care organizations millions of dollars each year, particularly among venture capital- and private equity-backed companies
• Trends in public oversight of private equity backed investments in health care

Chris Bell, CPA, National Health Care Industry Tax Leader and National Practice Leader, Medical Groups & Physicians, Moss Adams

Chris has practiced public accounting since 2005. He provides tax, strategic planning, and transaction planning services to health care organizations. He’s a frequent speaker and author on tax reform, the Affordable Care Act, and health care policy.

Erika Williams, CPA, Partner, Moss Adams

Erika has practiced public accounting since 2014, specializing in health care, professional services, and private clients. She has a strong foundation in working with closely held pass-through entities, assisting with federal, state, and local income tax compliance. In addition to compliance services, Erika offers consulting on a variety of matters including quarterly estimate and distribution calculations, compensation formulas, and buy-ins and outs.

Travis Riley, Partner, Moss Adams

Travis has provided research tax credit studies to companies claiming R&D credits since 2006. He’s a leader in the firm’s R&D offerings in California, helping both companies and business owners save millions of dollars in taxes each year. Travis has significant experience helping companies identify, increase, document, and support claims related to R&D tax credits, orphan drug credits, and other R&D incentives.